TimothyPatrickWhelanMD
Pulmonology • Charleston, SCCritical Care Medicine, Interstitial Lung Diseases, Lung Transplantation Medicine, Pleural Disease
Physician
Dr. Whelan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
171 Ashley Ave
Charleston, SC 29425Phone+1 843-792-1414Fax+1 843-792-1729
Education & Training
University of WashingtonFellowship, Pulmonary Disease and Critical Care Medicine, 2000 - 2003
University of ColoradoResidency, Internal Medicine, 1995 - 1998
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1995
Certifications & Licensure
SC State Medical License 2010 - 2025
MN State Medical License 2003 - 2010
WA State Medical License 2000 - 2005
CO State Medical License 1998 - 2001- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jan 31
- A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis Start of enrollment: 2016 May 26
- Hypofractionated LocoRegional Radiotherapy in Breast Cancer Start of enrollment: 2021 Feb 10
Publications & Presentations
PubMed
- 16 citationsTime to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO RegistryLaurie D. Snyder, Chris Mosher, Colin Holtze, Lisa Lancaster, Kevin R. Flaherty
BMJ Open Respiratory Research. 2020-07-01 - 85 citationsISHLT special reportReport of the ISHLT Working Group on Primary Lung Graft Dysfunction Part IV: Recipient-Related Risk Factors and MarkersMark L. Barr, Steven M. Kawut, Timothy P.M. Whelan, Reda E. Girgis, Heidi Böttcher
The Journal of Heart and Lung Transplantation. 2005-10-01 - 168 citationsEfficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trialGanesh Raghu, Kevin K. Brown, Harold R. Collard, Vincent Cottin, Kevin F. Gibson
The Lancet. Respiratory Medicine. 2017-01-01
Press Mentions
Some Cancer Patients May Not Need Treatments After SurgeryJune 14th, 2022- Some Cancer Patients Can Skip Treatments, 2 Studies ShowJune 8th, 2022
- Studies Pinpoint Which Patients Can Skip Cancer TreatmentsJune 7th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
